Wei Heng

Suzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Fc-enhanced anti-TIGIT antibody 30,278-IgG1 RMD amplifies antitumor immunity through effector cell activation and synergizes with PD-1 blockade.

Fc-enhanced anti-TIGIT antibody 30,278-IgG1 RMD amplifies antitumor immunity through effector cell activation and synergizes with PD-1 blockade.

Journal: Clinical immunology (Orlando, Fla.)
Published: February 06, 2026

US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors.

US-guided Percutaneous Radiofrequency Ablation for Secondary Hyperparathyroidism: Long-term Outcomes and Prognostic Factors.

Journal: Radiology
Published: April 16, 2024

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study.

Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study.

Journal: JMIR cancer
Published: December 28, 2022

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report.

Treatment Response to Immunotherapy After Crizotinib Resistance in a Patient With Pulmonary Sarcomatoid Carcinoma Harboring MET Exon 14 Skipping Mutation: A Case Report.

Journal: Clinical Medicine Insights. Oncology
Published: June 25, 2021

T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer.

T lymphocytes related biomarkers for predicting immunotherapy efficacy in non-small cell lung cancer.

Journal: Oncology letters
Published: June 27, 2020

Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.

Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 02, 2019

RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis.

RNPC1 inhibits non-small cell lung cancer progression via regulating miR-181a/CASC2 axis.

Journal: Biotechnology letters
Published: November 03, 2017

HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis.

HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis.

Journal: Biotechnology letters
Published: November 03, 2017

Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China.

Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China.

Journal: Thoracic cancer
Published: October 09, 2017

A case report: an EML4-ALK positive lung adenocarcinoma diagnosed 
with lymphoma previously

A case report: an EML4-ALK positive lung adenocarcinoma diagnosed 
with lymphoma previously

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: February 14, 2015

Endothelial cell protein C receptor (EPCR) is expressed by lung carcinoma and correlated with clinical parameters.

Endothelial cell protein C receptor (EPCR) is expressed by lung carcinoma and correlated with clinical parameters.

Journal: Clinical laboratory
Published: June 04, 2013

Inhibition of cellular growth and migration by suppression of endothelial protein C receptor (EPCR) in lung carcinoma cells.

Inhibition of cellular growth and migration by suppression of endothelial protein C receptor (EPCR) in lung carcinoma cells.

Journal: Oncology research
Published: January 01, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026